Skip to main content

Table 6 Plasma pharmacodynamics in MAD cohort

From: Safety and tolerability of BAN2401 - a clinical study in Alzheimer’s disease with a protofibril selective Aβ antibody

 

Placebo

MAD2

MAD3

MAD4

Plasma Aβ(1-40) mean (SD) concentration (pg/mL)

Maximal % change from baseline

-27.39 (48.98)

15.92 (97.17)

39.71 (17.91)

120.71 (53.21)

24 h post final dose

13.42 (28.09)

16.99a

17.50 (9.14)

86.20 (48.06)

  1. Percentage change from baseline in Aβ (1-40)
  2. amyloid β, MAD multiple ascending dose
  3. aInsufficient “n” to calculate SD